Teva Will Rebut Latest EU Competition Criticism
Supplementary Statement Of Objections Issued By Commission Over Modafinil
In the wake of the European Commission issuing Teva with a supplementary statement of objections over a historical “pay for delay” patent settlement agreement on modafinil with Cephalon, the Israeli firm has insisted on its right to reply.
